Anas Fathallah, PhD brings extensive expertise in translational and clinical pharmacology, with a strategic focus on building development paths that connect mechanism, biomarkers, and dosing rationale to clinical endpoints. He previously held clinical pharmacology roles at Biogen, where his experience with biologics development includes Alzheimer’s disease antibody programs (Biogen-developed amyloid-β–directed antibodies have been central to the company’s Alzheimer’s franchise).
Dr. Fathallah’s background spans protein therapeutics, clinical pharmacology and modeling, clinical development planning, regulatory communications, and rigorous early candidate nomination/selection. He is also Founder & CEO of LAPIX Therapeutics, a clinical-stage biopharmaceutical company developing antigen-agnostic immune tolerance restoration therapies.